Technology


Publications


Publications


No.YearTitleJournal
12021Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2Computational and Structural Biotechnology Journal
2021 Feb 27;19:1325-1334
22020Effective inhibition of C3a‐mediated pro‐inflammatory response by a human C3a‐specific protein binderBiotechnology and Bioengineering
2020 Jun;117(6):1904-1908
32020A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton’s tyrosine kinase and its drug-resistant variantBiochemical and Biophysical Research Communications
2020 May 21;526(1):8-13
42019Computer-aided Binding Mode Prediction and Affinity Maturation of LRR Protein 2 Binder without Structural DeterminationPLOS Computational Biology
2020 Aug 31;16(8):e1008150
52020A small-sized protein binder specific for human PD-1 effectively suppresses the tumor growth in tumor mouse modelJournal of Drug Targeting
2020 Apr;28(4):419-427
62019Prolonged half-life of small-sized therapeutic protein using serum albuminspecific protein binderJournal of Controlled Release
2019 Dec 10;315:31-39
72018Engineering and cytosolic delivery of a native regulatory protein and its variants for modulation of ERK2 signaling pathway

Biotechnology and Bioengineering

2018 Apr;115(4):839-849

82017Intracellular protein delivery system using a target-specific repebody and translocation domain of bacterial exotoxin
ACS Chemical Biology
2017 Nov 17;12(11):2891-2897
92017A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors
Theranostics
2017 Jun 25;7(10):2620-2633
102016Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody
Biochemical and Biophysical Research Communications
2016 Sep 2;477(4):1072-1077
112016Engineering of bacterial exotoxins for highly efficient and receptor-specific intracellular delivery of diverse cargos
Biotechnology and Bioengineering
2016 Aug;113(8):1639-46
122016Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage
PLOS one
2016 Mar 25;11(3):e0152522
132015Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy
Angewandte Chemie
2015 Oct 5;54(41):12020-4
142014A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer
Molecular Therapy
2014 Jul;22(7):1254-1265
152014Protein Binder for Affinity Purification of Human Immunoglobulin Antibodies
Analytical Chemistry
2014 Jun 17;86(12):6019-25
162012Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering
PNAS
2012 Feb 28;109(9):3299-304

상호명  주식회사 프로엔테라퓨틱스  |  대표자  이일한

전화번호  031-759-8788  |  팩스번호  031-759-8850

이메일  proen@proentherapeutics.com

판교지사  경기도 성남시 수정구 청계산로 686 반도아이비밸리 301호

대전본사  대전광역시 유성구 테크노4로 17 대덕비즈센터 B동 204호

Copyright ⓒ proentherapeutics Co., All Rights Reserved.


상호명  주식회사 프로엔테라퓨틱스  |  대표자  이일한

전화번호  031-759-8788  |  팩스번호  031-759-8850  |  이메일  proen@proentherapeutics.com

판교지사  경기도 성남시 수정구 청계산로 686 반도아이비밸리 301호  |  대전본사  대전광역시 유성구 테크노4로 17 대덕비즈센터 B동 204호

Copyright ⓒ proentherapeutics Co., All Rights Reserved.